BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 21561919)

  • 21. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
    Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
    J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
    Gao Y; Bergman I
    J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.
    Shulak L; Beljanski V; Chiang C; Dutta SM; Van Grevenynghe J; Belgnaoui SM; Nguyên TL; Di Lenardo T; Semmes OJ; Lin R; Hiscott J
    J Virol; 2014 Mar; 88(5):2927-40. PubMed ID: 24371063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling.
    Malilas W; Koh SS; Srisuttee R; Boonying W; Cho IR; Jeong CS; Johnston RN; Chung YH
    Cancer Gene Ther; 2013 Feb; 20(2):125-32. PubMed ID: 23306614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A recombinant vesicular stomatitis virus bearing a lethal mutation in the glycoprotein gene uncovers a second site suppressor that restores fusion.
    Stanifer ML; Cureton DK; Whelan SP
    J Virol; 2011 Aug; 85(16):8105-15. PubMed ID: 21680501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.
    Ayala-Breton C; Suksanpaisan L; Mader EK; Russell SJ; Peng KW
    Mol Ther; 2013 Oct; 21(10):1930-7. PubMed ID: 23842448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
    Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R
    Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations.
    Clarke DK; Nasar F; Lee M; Johnson JE; Wright K; Calderon P; Guo M; Natuk R; Cooper D; Hendry RM; Udem SA
    J Virol; 2007 Feb; 81(4):2056-64. PubMed ID: 17151112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.
    Ahmed M; Cramer SD; Lyles DS
    Virology; 2004 Dec; 330(1):34-49. PubMed ID: 15527832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.
    Ahmed M; Puckett S; Lyles DS
    Cancer Gene Ther; 2010 Dec; 17(12):883-92. PubMed ID: 20725101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
    Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
    J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
    Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
    Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness.
    Fredericksen BL; Whitt MA
    Virology; 1998 Jan; 240(2):349-58. PubMed ID: 9454708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric measles viruses with a foreign envelope.
    Spielhofer P; Bächi T; Fehr T; Christiansen G; Cattaneo R; Kaelin K; Billeter MA; Naim HY
    J Virol; 1998 Mar; 72(3):2150-9. PubMed ID: 9499071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.
    Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Melcher A; Vile R
    Mol Ther; 2011 Jan; 19(1):150-8. PubMed ID: 20959810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
    Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
    J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
    Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
    Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
    Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.